mRNA In Situ Hybridization (HistoSonda)

Autor: Ainoha Hernándiz, Carles Casterá, Federico Rojo, Irune Ruiz, Alicia Cordoba, Javier Martin de Francisco Hernandez, Francesc Riu, Jose Miguel Lazaro, Ricardo Rezola, Tomás García-Caballero, Luis Polo, Victoria M. Coupe, Rafael Cano Muñoz, Juan de Dios Barranco, David Hardisson, Francisco Sevilla, Marcos Martínez Benaclocha, J.M. de la Cámara de las Heras, Javier Alba, Laia Bernet

Publikováno v: Bernet, L, Benaclocha, M M, Castera, C, Munoz, R C, Sevilla, F, Alba, J, Barranco, J D, Cordoba, A, Garcia-Caballero, T, Hardisson, D, Hernandez, J M D, Lazaro, J M, Polo, L, Riu, F, Rezola, R, Rojo, F, Ruiz, I, Hernandiz, A, de las Heras, J M D & Coupé, V M H 2012, ' mRNA In Situ Hybridization (HistoSonda): A New Diagnostic Tool for HER2-Status in Breast Cancer-A Multicentric Spanish Study ', Diagnostic Molecular Pathology, vol. 21, no. 2, pp. 84-92 . https://doi.org/10.1097/PDM.0b013e3182360b0a
Diagnostic Molecular Pathology, 21(2), 84-92. Lippincott Williams and Wilkins

Monoclonal therapies could represent baseline-personalized medicine for patients with neoplasia. One of the most successful examples is Trastuzumab, a humanized antibody against epidermal growth factor receptor 2. Human epidermal growth factor recept

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::166c23c6c549afb1d59af783492d2245
https://doi.org/10.1097/pdm.0b013e3182360b0a